News Datroway joins Trodelvy for frontline TNBC in the EU AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.
News Ultomiris fail mars AZ's strong Q2 results AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side.
News EU clears AZ's SERD camizestrant, as FDA review drags on AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.
News AstraZeneca adds another Chinese asset, from Dizal AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.
R&D Go north: Life sciences excellence shines bright in Sweden Gothenburg is Sweden's fastest-growing and second largest city region and one of Europe's leading innovation regions.
News AZ, Ionis hit by unexpected Wainua trial failure Prospects for AstraZeneca and Ionis' Wainua have been severely dented by a failed trial in ATTR cardiomyopathy, weighing on the shares of both firms.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.